Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
ROVI held its 2025 General Shareholders’ Meeting
ROVI continues with its shareholder remuneration policy after completing the third consecutive share buyback programme last year and...
5 min
18/06/2025
First three months 2025 results press release
​Operating revenue in the first quarter of 2025 was 154.9 million euros, a 2% increase on the first quarter of 2024, mainly due to the...
2 min
08/05/2025
2025 Capital Markets Day presentation
ROVI forecasts that its 2024 operating revenue will be multiplied by between 1.5 and 1.8 in six years, driven primarily by an increase...
1 min
25/03/2025